Daiichi Sankyo, Glycotope in ADC PactBy
Daiichi Sankyo and Glycotope, a Berlin, Germany-headquartered biotechnology company, have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody, PankoMab-GEX.
Under the agreement, once a feasibility study has been successfully completed, Daiichi Sankyo has the right to exercise its option for worldwide exclusive rights to develop and commercialize PankoMab-GEX ADC. If Daiichi Sankyo exercises these rights, Glycotope will receive an upfront payment as well as development and sales milestone payments plus royalties. Specific financial terms were not disclosed.
Source: Daiichi Sankyo and Glycotope